Highest-materiality recent filing
Solventum adopts new Executive Severance Plan effective June 1, 2026
Provides 12 months base salary plus prorated incentive for CEO direct reports; current execs retain 18 months for 2 years.
Elected Class II directors Albán, DeVore, Edwards, Harris with majority support (approx 114M-115M for, 27M-28M against).
Solventum Q1 sales $2.0B (organic +2.1%), adj. EPS $1.48, affirms FY guidance
Reported sales $2.007B, down 3.0%; organic sales up 2.1%, ahead of expectations.
Solventum CAO Mary Wilcox to retire upon successor appointment
Mary Wilcox notified intent to retire and resign as Chief Accounting Officer on March 20, 2026.
Q4 reported sales $1,998M (-3.7% YoY); organic sales +3.5% driven by MedSurg and Dental.
Solventum CEO reviews first standalone year; cites volume growth, acquisitions, $1B buyback
Six consecutive quarters of positive volume growth; full-year 2025 outlook raised multiple times.
Solventum Q3 organic sales +2.7%; raises FY adj. EPS guidance to $5.98-$6.08
Q3 reported sales $2.1B (+0.7% YoY); organic sales +2.7% driven by Dental Solutions and HIS.
Solventum appoints Heather Knight as Chief Commercial Officer; Chris Barry to depart
Heather Knight appointed to new Chief Commercial Officer role effective Nov 10, 2025, overseeing MedSurg, Dental, Health Information Systems.
Solventum upsizes note tender offers to $2B, prices purchases at premiums
Increased aggregate cap from $1.75B to $2B; Pool 1 max raised to $1.5B and Tender SubCap to $650M.
Solventum completes $4.0B sale of Purification & Filtration business to Thermo Fisher
Completed sale of P&F business to Thermo Fisher for $4.0B cash on September 1, 2025.
Solventum commences $1.75B note tender offers contingent on Thermo Fisher deal proceeds
Up to $1.75B aggregate purchase price: Pool 1 ($1.25B) covers 2027-2031 notes, Pool 2 ($500M) covers 2054 & 2064 notes.
Solventum announces secondary offering of 8.8M shares by 3M for ~$648M gross proceeds
3M sells 8,800,000 shares of Solventum common stock in secondary offering.
Solventum amends purification & filtration sale to Thermo Fisher; consideration reduced to ~$4.0B
Amended agreement on June 25, 2025 excludes drinking water filtration business; cash consideration cut from $4.1B to ~$4.0B.
Solventum Q2 sales up 3.9% to $2.2B; raises FY organic growth & EPS guidance
GAAP diluted EPS $0.51; adjusted diluted EPS $1.69 (+8.3% YoY).
Solventum amends Thermo Fisher deal to exclude water filtration business; price reduced to ~$4.0B
Solventum and Thermo Fisher amend agreement to exclude drinking water filtration business; cash consideration cut from ~$4.1B to ~$4.0B.
Net sales $2.07B (+2.6% reported, +4.3% organic); net income $137M (-42.2% YoY).
Four Class I nominees elected: Eisenberg, Mily, Weiland, Wendell — each with >135M votes for.
Solventum Q4 2024: GAAP EPS $0.17, adj. EPS $1.41, organic sales +2.3%
GAAP diluted EPS $0.17; adjusted EPS $1.41; sales $2,074M (+1.9% reported, +2.3% organic).
Solventum sells purification and filtration business to Thermo Fisher for $4.1B
Thermo Fisher to acquire Solventum's purification and filtration business for $4.1B cash, subject to customary adjustments.
Solventum Q3 sales flat at $2.082B; adjusted EPS $1.64, raises FY guidance
GAAP EPS $0.70, adjusted EPS $1.64; operating income $275M GAAP, $475M adjusted.
Solventum adopts enhanced change-in-control severance plan for top executives
New plan effective Oct 30, 2024 covers CEO, CFO, CAO, and other key executives with enhanced change-in-control severance.
Removed requirement for nominating stockholder to disclose info about 'any principal competitor'; financial support disclosure clarified.
Solventum Q2 GAAP EPS $0.51, adj EPS $1.56; raises full-year guidance
Reported sales $2.081B (+0.2% YoY); organic sales +1.3%; MedSurg and HIS drove growth.
Solventum grants equity awards to CEO (102,946 RSUs, 102,946 PSUs, 253,406 inducement PSUs) and CFO
CEO Bryan Hanson: 102,946 RSUs, 102,946 annual PSUs, 253,406 inducement PSUs granted.
Solventum reports Q1 sales $2.02B, adjusted EPS $2.08; reaffirms 2024 guidance
Sales $2.016B (+0.2% reported, +0.9% organic); GAAP EPS $1.37, adjusted EPS $2.08.
Solventum elects Shirley A. Edwards, former EY partner, to board effective April 12, 2024
Shirley A. Edwards, a former EY Global Client Service Partner (2017-2022), elected to Solventum's Board as a Class II director, term expiring at 2026 annual meeting.
Solventum completes 3M spin-off, begins trading on NYSE as SOLV
80.1% of Solventum shares distributed to 3M stockholders on April 1, 2024; spin-off effective 3:30 a.m. ET.
Solventum spin-off from 3M effective; distribution 1:4, record date March 18, completion April 1
Registration statement declared effective March 13, 2024; spin-off proceeding as planned.
On April 12, 2024, the Board of Directors (the “Board”) of Solventum Corporation (the “Company”) elected Shirley A. Edwards to the Company’s Board, effective April 12, 2024.
Paul Harrington Chief Supply Chain Officer
Marcela Kirberger Chief Legal Affairs Officer, Corporate Secretary
Tammy Gomez Chief Human Resources Officer
Mary Wilcox Senior Vice President, Controller and Chief Accounting Officer
Amy Landucci Chief Information and Digital Officer
Bryan Hanson Chief Executive Officer
Chris Barry Executive Vice President and Group President, Medical Solutions
Wayde McMillan Chief Financial Officer
Max materiality 0.90 · Median 0.70 · Most common event other_material